ClinicalTrials.gg
CompletedNCT07937046Updated Nov 13, 2026

Single and Multiple Ascending Dose Study of KRP-203 in Healthy Japanese Adults

A Phase 1 interventional study of KRP-203 and Placebo in Healthy Vollunteer, sponsored by Priothera SAS. Completed. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Priothera SAS · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2011, 15 years 6 months ago, and no results have been posted to the registry.
  • Registered 15 years 8 months after the study started (first participant enrolled Jan 2011, registered Oct 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
20 Years to 55 Years
Sex
All
01

Study summary

KRP-203 is an experimental medicine taken as a capsule. It keeps some white blood cells (lymphocytes) inside the lymph nodes, so fewer circulate in the blood. It may help treat diseases where the immune system attacks the body, such as ulcerative colitis. After earlier studies in the United Kingdom, this study tested KRP-203 for the first time in healthy Japanese adults.

What did the study want to find out?

The main goal was to learn how safe and well tolerated KRP-203 is after one dose and after daily doses for 28 days. It also measured how much medicine gets into the blood, how long it stays, and its effect on lymphocyte counts and heart rate.

Who could take part?

Healthy Japanese men and women aged 20 to 55 years with a body mass index of 18.5 to under 25. Women could only take part if they could not become pregnant. People could not take part if they smoked, took regular medicines, or had heart rhythm problems, lung disease, eye swelling (macular edema), allergies, immune disease, liver or kidney disease, or infections such as hepatitis or HIV.

How was the study done?

The study had 2 parts at one center in Japan. In each group, participants were assigned by chance to KRP-203 or placebo (a dummy capsule). Neither participants nor study doctors knew who received which.

Part 1 (single dose): 40 people in 4 groups of 10 (8 KRP-203, 2 placebo) received one dose of 0.3, 1, 2 or 3 mg. Each higher dose followed a safety review. Participants stayed at the center for 7 days, with check-ups up to Day 15.

Part 2 (daily doses): 24 people in 2 groups of 12 (9 KRP-203, 3 placebo) took 1.2 or 2 mg once a day for 28 days, after Part 1 was completed safely. Participants stayed at the center for 32 days, with check-ups up to Day 49.

Everyone received a placebo capsule the day before the first dose for baseline measurements.

What tests were done?

Health checks, blood pressure, heart rate, ECG and 24-hour heart monitoring, blood and urine tests, breathing tests and nerve checks. Part 2 participants also had eye examinations.

What were the possible risks? In earlier studies, KRP-203 slowed the heart rate, mainly in the first hours after the first dose, and sometimes caused a temporary heart rhythm disturbance at higher doses. Other effects included headache, tiredness, nausea, and temporary changes in breathing and liver tests. Fewer lymphocytes may increase the risk of infection. Men had to use reliable contraception until 3 months after the study.

Read the detailed description

Background and rationale KRP-203 is an oral immunomodulator that is phosphorylated in vivo to its active metabolite, KRP-203 phosphate (KRP-203-P), a selective sphingosine-1-phosphate receptor 1 (S1P1) agonist. S1P1 receptor internalization sequesters lymphocytes in secondary lymphoid organs and reduces circulating lymphocytes, including T cells. KRP-203 was effective in animal models of inflammatory bowel disease and experimental autoimmune encephalomyelitis.

In single (0.01-40 mg) and multiple (0.3-3 mg for 14-28 days) ascending dose studies in healthy adults in the United Kingdom, KRP-203 produced dose-dependent lymphocyte reduction and an initial reduction in heart rate. Second-degree AV block and other adverse events occurred at higher doses, and reversible liver enzyme elevations were observed. The maximum tolerated single dose was 40 mg, limited by symptomatic bradycardia. This study evaluated safety, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy Japanese adults for comparison with the overseas data, and was designed following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA).

Study conduct All participants received a single dose of placebo on Day -1 (pre-assignment) to obtain baseline safety and PD data, and were then randomized within their dose step. Escalation to the next step required review of safety data from the previous step by the investigator and sponsor, and Study 2 started only after safety was confirmed at the highest dose of Study 1. Pre-defined criteria for consulting the sponsor before escalation included symptomatic bradycardia requiring treatment, Mobitz type II or third-degree AV block, or severe infection (CTCAE Grade 3 or higher) in two or more participants in the same step.

Study 1 (single dose): doses were given after a fast of at least 10 hours. Participants stayed at the study site from Day -2 to Day 5, with follow-up visits on Days 7 and 10 and an end-of-study visit on Day 15.

Study 2 (multiple dose): the Day 1 dose was given fasted, and doses on Days 2-28 were given within 30 minutes after breakfast. Participants stayed at the study site from Day -2 to Day 30, with follow-up visits on Days 32, 35, 38 and 42 and an end-of-study visit on Day 49.

During the inpatient stay, alcohol, caffeine and other xanthine-containing products were prohibited. Grapefruit and St. John's wort were prohibited from the day before admission. Male participants were required to use two reliable contraceptive methods, including a barrier method, from admission until 3 months after the end-of-study visit, because of teratogenic findings in animal studies.

Safety monitoring included 12-lead ECG and Holter monitoring around the first dose in both studies, with additional Holter periods on Days 5, 14 and 28 in Study 2. Spirometry, neurological examinations and, in Study 2, ophthalmological examinations including optical coherence tomography were also performed.

Statistical methods Sample size was based on the overseas studies and the feasibility of evaluating safety and PK, allowing for dropouts. The safety analysis set included all dosed participants with post-dose safety data. Safety data were summarized by study, dose and time point. PK and PD data were summarized descriptively and analyzed in an exploratory manner. The treatment code was broken after all steps were completed and the safety and PD data were locked.

02

Conditions studied

  • Healthy Vollunteer

Keywords

  • MOCRAVIMOD
  • S1P modulator
  • Pharmacokinetics
  • Pharmacodynamics
03

In context

Lead sponsor

Priothera SAS is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese men or women aged 20-55 years (inclusive) at the time of
  • Vital signs at screening and admission within the following ranges:
  • Body temperature 35.0-37.5 °C
  • Diastolic blood pressure 40-89 mmHg
  • Pulse rate 50-100 bpm
  • Women must meet one of the following:
  • Surgically sterilized or hysterectomy at least 6 months before admission
  • , defined as no menstruation without another medical reason for at least 2 years before admission
  • (BMI) of 18.5 to \<25.0 kg/m² at screening and admission
  • Judged healthy by the investigator, based on interview, observation and examinations at screening and admission
  • Able to understand the study and willing to give voluntary written informed consent

Exclusion criteria

Exclusion Criteria:

  • Smokers: smoked within 3 months before admission, or positive urine cotinine test at screening or admission
  • Use of medicines:
  • Any prescription drug within 4 weeks before admission (except drugs used for the protocol's eye examinations)
  • Any over-the-counter drug within 2 weeks before admission
  • Expected need for any of these during the study
  • Any within 2 months before admission
  • Participation in another clinical trial of an approved active ingredient within 3 months, or of an unapproved active ingredient within 4 months, before admission
  • Blood donation or blood draws before screening:
  • ≥800 mL in total within 1 year
  • ≥400 mL of whole blood within 3 months
  • ≥200 mL of whole blood within 1 month
  • Blood components (e.g., plasma or ) within 2 weeks
  • Anemia, or \<13.5 g/dL (men) or \<11.3 g/dL (women) at screening
  • Signs of acute or chronic infection, or C-reactive protein (CRP) >0.3 mg/dL at screening (eligible if ≤0.3 mg/dL on re-test)
  • Current or past history, or family history (up to second-degree relatives), of any of the following cardiovascular conditions:
  • Second-degree AV block (Mobitz type I or II), third-degree AV block or related arrhythmia
  • Long syndrome
  • findings, including QTcB >450 ms (men) or >470 ms (women), PR >240 ms, or QRS >120 ms
  • Hypokalemia or hypomagnesemia
  • Heart failure or left ventricular dysfunction
  • Clinically significant atherosclerotic disease (angina pectoris, coronary artery disease or myocardial infarction)
  • Current or past autonomic nervous system dysfunction (e.g., recurrent syncope or palpitations)
  • Current or past acute or chronic pulmonary function impairment, treated or untreated, including asthma and
  • % ≤80% of predicted at screening
  • Current or past macular edema
  • Current or past drug allergy, food allergy or atopy
  • Hay fever (pollinosis) symptoms at admission
  • Current or past clinically evident immune system disease (other than allergy, atopy or hay fever listed above)
  • History of surgery or medical disease that may significantly affect drug absorption, distribution, metabolism or excretion, or that may put the participant at risk, including:
  • Inflammatory bowel disease, gastritis, ulcer, or gastrointestinal or rectal bleeding
  • Gastrointestinal surgery (e.g., gastrectomy, gastroenterotomy, cholecystectomy, enterectomy)
  • Pancreatic injury or pancreatitis
  • Abnormal liver function tests indicating liver disease ( or ALT >40 U/L at screening; eligible if ≤40 U/L on re-test)
  • Clinically significant abnormalities in creatinine, BUN or urine tests indicating renal impairment
  • Urinary tract obstruction or dysuria
  • Metabolic disease
  • Blood counts at screening or admission outside the following limits:
  • White blood cells \<3,900/µL or >9,800/µL
  • Lymphocytes \<800/µL
  • Platelets \<100,000/µL
  • Positive test at screening for surface antigen, antibody, antigen or antibody, or syphilis
  • Negative varicella-zoster virus (VZV) IgG antibody at screening (multiple-dose part only)
  • History of drug addiction or alcoholism, or suspected current drug addiction or alcoholism
  • Pregnant or breastfeeding
  • Considered unable to follow the investigator's instructions or the protocol
  • Otherwise considered ineligible by the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    0.3 mg KRP-203 single dose

    Once under the fasting conditions

    Drug: KRP-203

  • Experimental
    1.0 mg KRP-203 single dose

    Once under the fasting conditions

    Drug: KRP-203

  • Experimental
    2.0 mg KRP-203 single dose

    Once under the fasting conditions

    Drug: KRP-203

  • Experimental
    3.0 mg KRP-203 single dose

    Once under the fasting conditions

    Drug: KRP-203

  • Experimental
    1.2 mg KRP-203

    Once under the fasting conditions on Day 1 Once after breakfast on Days 2 to 28 (for 28 days in total)

    Drug: KRP-203

  • Experimental
    2.0 mg KRP-203

    Once under the fasting conditions on Day 1 Once after breakfast on Days 2 to 28 (for 28 days in total)

    Drug: KRP-203

  • Placebo comparator
    Placebo Comparator 1

    Healthy participants randomized to placebo within each multiple-dose group (3 per group, 2 groups) received placebo orally on Day -1 and once daily for 28 days.

    Other: Placebo

  • Placebo comparator
    Placebo Comparator 2

    Healthy participants randomized to placebo within each single-dose group (2 per group, 4 groups) received a single oral dose of placebo on Day -1 and on Day 1.

    Other: Placebo

Interventions

  • DrugKRP-203
  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) (symptoms and signs, physical examinations, ECG, and laboratory tests)

    An AE was any untoward medical occurrence in a participant after administration of study drug, whether or not considered related to study drug. AEs included subjective symptoms, objective findings, and abnormal findings on physical examination (vital signs, spirometry, neurological and ophthalmological examinations), 12-lead ECG, Holter monitoring and laboratory tests (hematology, blood chemistry, urinalysis) that were judged by the investigator to be clinically significant. Each participant was counted once.

    Time frame: Day 1 up to Day 15 (single-dose arms) or Day 49 (multiple-dose arms)

  2. Number of Participants With Adverse Drug Reactions (ADRs) (symptoms and signs, physical examinations, ECG, and laboratory tests)

    An ADR was an AE for which a causal relationship to study drug could not be ruled out, as judged by the investigator. ADRs included symptoms, signs and clinically significant abnormal findings on physical examination, 12-lead ECG, Holter monitoring and laboratory tests. Each participant was counted once.

    Time frame: Day 1 up to Day 15 (single-dose arms) or Day 49 (multiple-dose arms)

Secondary outcomes

  1. Maximum Blood Concentration (Cmax) of KRP-203 and KRP-203-P After a Single Dose

    Cmax is the maximum observed concentration of KRP-203 and its active metabolite KRP-203 phosphate (KRP-203-P), measured in ng/mL.

    Time frame: Pre-dose and at multiple time points up to Day 15 after a single dose on Day

  2. Time to Maximum Blood Concentration (Tmax) of KRP-203 and KRP-203-P After a Single Dose

    Tmax is the time to reach the maximum observed concentration of KRP-203 and KRP-203-P, measured in hours.

    Time frame: Day 1 pre-dose up to Day 15 (336 hours post-dose)

  3. Lag Time (Tlag) of KRP-203 and KRP-203-P After a Single Dose

    Tlag is the time from dosing to the first measurable concentration of KRP-203 and KRP-203-P, measured in hours.

    Time frame: Pre-dose and at multiple time points up to Day 15 after a single dose on Day 1

  4. Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of KRP-203 and KRP-203-P After a Single Dose

    AUClast of KRP-203 and KRP-203-P, measured in ng\*h/mL.

    Time frame: Pre-dose and at multiple time points up to Day 15 after a single dose on Day 1

  5. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of KRP-203 and KRP-203-P After a Single Dose

    AUCinf of KRP-203 and KRP-203-P, measured in ng\*h/mL.

    Time frame: Pre-dose and at multiple time points up to Day 15 after a single dose on Day 1

  6. Elimination Half-life (T1/2) of KRP-203 and KRP-203-P After a Single Dose

    T1/2 is the terminal elimination half-life of KRP-203 and KRP-203-P, measured in hours.

    Time frame: Pre-dose and at multiple time points up to Day 15 after a single dose on Day 1

  7. Maximum Blood Concentration (Cmax) of KRP-203 and KRP-203-P on Day 1 and at Steady State (Cmax,ss) on Day 28

    Maximum observed concentration of KRP-203 and KRP-203-P after the first dose (Day 1) and at steady state (Day 28) during once-daily dosing for 28 days, measured in ng/mL.

    Time frame: Day 1 and Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  8. Time to Maximum Blood Concentration of KRP-203 and KRP-203-P on Day 1 (Tmax) and Day 28 (Tmax,ss)

    Time to reach the maximum observed concentration of KRP-203 and KRP-203-P after the first dose (Day 1) and at steady state (Day 28), measured in hours.

    Time frame: Day 1 and Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  9. Lag Time (Tlag) of KRP-203 and KRP-203-P After the First Dose

    Time from the first dose to the first measurable concentration of KRP-203 and KRP-203-P, measured in hours.

    Time frame: Day 1 (pre-dose and at multiple time points up to 24 hours post-dose)

  10. Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h) on Day 1 and Over the Dosing Interval at Steady State (AUCtau) on Day 28 of KRP-203 and KRP-203-P

    AUC0-24h after the first dose (Day 1) and AUCtau at steady state (Day 28) of KRP-203 and KRP-203-P, measured in ng\*h/mL.

    Time frame: Day 1 and Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  11. Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of KRP-203 and KRP-203-P After the Last Dose

    AUClast of KRP-203 and KRP-203-P after the last dose on Day 28, measured in ng\*h/mL.

    Time frame: Day 28 (pre-dose) up to Day 42

  12. Minimum Blood Concentration at Steady State (Cmin,ss) of KRP-203 and KRP-203-P

    Minimum observed concentration of KRP-203 and KRP-203-P over the dosing interval at steady state, measured in ng/mL.

    Time frame: Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  13. Average Blood Concentration at Steady State (Cav,ss) of KRP-203 and KRP-203-P

    Average concentration of KRP-203 and KRP-203-P over the dosing interval at steady state (AUCtau divided by the 24-hour dosing interval), measured in ng/mL.

    Time frame: Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  14. Elimination Half-life (T1/2) of KRP-203 and KRP-203-P After the Last Dose

    Terminal elimination half-life of KRP-203 and KRP-203-P after the last dose on Day 28, measured in hours.

    Time frame: Day 28 (pre-dose) up to Day 42

  15. Accumulation Ratio (Racc) of KRP-203 and KRP-203-P

    Racc is the ratio of AUCtau on Day 28 to AUC0-24h on Day 1 for KRP-203 and KRP-203-P (unitless ratio).

    Time frame: Day 1 and Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  16. Degree of Fluctuation (Fluc) at Steady State of KRP-203 and KRP-203-P

    Fluc is the peak-to-trough fluctuation at steady state, calculated as (Cmax,ss - Cmin,ss) / Cav,ss x 100, for KRP-203 and KRP-203-P, measured in percent.

    Time frame: Day 28 (pre-dose and at multiple time points up to 24 hours post-dose)

  17. Change From Baseline in Peripheral Blood Lymphocyte Count

    Absolute lymphocyte count was calculated from the white blood cell count and differential in peripheral blood, measured in cells/µL. Baseline is the pre-dose value on Day 1.

    Time frame: Baseline (Day 1 pre-dose) and at multiple time points up to Day 15 (single-dose arms) or Day 49 (multiple-dose arms)

  18. Change From Baseline in Heart Rate

    Heart rate, measured in beats per minute (bpm), was assessed by vital signs, 12-lead ECG and Holter monitoring. Baseline is the corresponding time-matched value on Day -1 (placebo pre-assignment day).

    Time frame: Baseline (Day -1) and at multiple time points up to Day 15 (single-dose arms) or Day 49 (multiple-dose arms)

  19. Change From Baseline in Peripheral Blood White Blood Cell Subset Counts (Multiple-Dose Arms)

    Counts of white blood cell subsets were measured by flow cytometry, in cells/µL. Each subset was reported separately: CD3+ (T cells), CD4+ (helper T cells), CD8+ (cytotoxic T cells), CD14+ (monocytes), CD16+ (NK cells), CD19+ (B cells), CD45RO+ (memory cells) and CD45RA+ (naive cells). Baseline is the pre-dose value on Day 1.

    Time frame: Baseline (Day 1 pre-dose) and at multiple time points up to Day 49

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in May 2011, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Nov 13, 2026
StartActual
Jan 17, 2011
Primary completionActual
May 16, 2011
CompletionActual
Jan 24, 2012
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937046
Lead sponsor
Priothera SAS
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Jan 17, 2011
Primary completion
May 16, 2011
Completion
Jan 24, 2012
Last update
Nov 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion